adalimumab

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pyoderma Gangrenosum

Conditions

Pyoderma Gangrenosum

Trial Timeline

Oct 27, 2017 → Apr 21, 2020

NCT ID

NCT03311464

About adalimumab

adalimumab is a phase 3 stage product being developed by AbbVie for Pyoderma Gangrenosum. The current trial status is completed. This product is registered under clinical trial identifier NCT03311464. Target conditions include Pyoderma Gangrenosum.

What happened to similar drugs?

1 of 5 similar drugs in Pyoderma Gangrenosum were approved

Approved (1) Terminated (5) Active (0)

✅sisomicinMerckApproved

❌gevokizumab + Placebo + gevokizumab open-labelXOMAPhase 3

❌gevokizumabXOMAPhase 3

❌gevokizumab + Placebo + gevokizumab open-labelXOMAPhase 3

❌vilobelimab + PlaceboInflaRxPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05414201	Approved	Completed	Jul 7, 2022	Jun 10, 2024	Non-infectious Intermediate Posterior- or Pan-uveitis
NCT04183608	Approved	Recruiting	Jan 14, 2020	May 1, 2028	Ulcerative Colitis
NCT03311464	Phase 3	Completed	Oct 27, 2017	Apr 21, 2020	Pyoderma Gangrenosum
NCT03261102	Pre-clinical	Active	Jan 17, 2017	Jun 1, 2025	Crohn Disease
NCT02897115	Approved	Terminated	Sep 12, 2016	Dec 21, 2017	Axial Spondyloarthritis
NCT02904902	Phase 3	Completed	Sep 6, 2016	May 30, 2019	Hidradenitis Suppurativa
NCT02668640	Pre-clinical	Completed	May 1, 2016	Aug 13, 2018	Rheumatoid Arthritis
NCT02750800	Pre-clinical	Completed	Apr 7, 2016	Apr 3, 2018	Rheumatoid Arthritis
NCT02739828	Pre-clinical	Completed	Apr 7, 2016	Mar 28, 2018	Hidradenitis Suppurativa
NCT02634541	Approved	UNKNOWN	Jan 1, 2016	Dec 1, 2017	Ankylosing Spondyloarthritis
NCT02632175	Phase 3	Completed	Nov 26, 2015	Apr 8, 2025	Ulcerative Colitis
NCT02533375	Phase 3	Completed	Sep 28, 2015	Jul 20, 2017	Generalized Pustular Psoriasis (GPP)
NCT02499783	Phase 3	Completed	Aug 17, 2015	Dec 15, 2017	Crohn's Disease
NCT02198651	Approved	Completed	Jan 5, 2015	Aug 8, 2018	Rheumatoid Arthritis
NCT02333383	Pre-clinical	Completed	Dec 31, 2014	Aug 8, 2017	Ankylosing Spondylitis
NCT02539849	Pre-clinical	Completed	Dec 1, 2014	Dec 19, 2017	Crohn Disease
NCT02185014	Phase 3	Completed	Aug 12, 2014	Nov 3, 2017	Crohn's Disease
NCT02148718	Approved	Completed	Jun 1, 2014	Jan 1, 2017	Moderate to Severe Crohn's Disease
NCT02065622	Phase 3	Completed	Mar 27, 2014	Nov 11, 2019	Ulcerative Colitis (UC)
NCT02016482	Phase 3	Completed	Jan 1, 2014	Apr 1, 2016	Nail Psoriasis

Competing Products

11 competing products in Pyoderma Gangrenosum

See all competitors

Product	Company	Stage	Hype Score
Ixekizumab	Eli Lilly	Phase 2	35
sisomicin	Merck	Approved	35
secukinumab 150 mg (2 injections per dose	Novartis	Phase 2	27
Secukinumab	Novartis	Phase 1/2	32
Deucravacitinib	Bristol Myers Squibb	Phase 1	21
gevokizumab	XOMA	Phase 2	25
gevokizumab + Placebo + gevokizumab open-label	XOMA	Phase 3	22
gevokizumab	XOMA	Phase 3	22
gevokizumab + Placebo + gevokizumab open-label	XOMA	Phase 3	22
vilobelimab + Placebo	InflaRx	Phase 3	22
vilobelimab	InflaRx	Phase 2	25